UP!

CPRX $3.16   View long term graphs

Catalyst Pharmaceutical Partners, Inc.
Type
Public company
Traded as NASDAQ: CPRX
Industry Biotechnology
Headquarters Coral Gables, FL, United States
Key people
Patrick J. McEnany, Co-Founder, Chairman, President and Chief Executive Officer
Products in development
Revenue US$ 0 million (2014)
Operating income
Decrease US$ -15.5 million (2014)
Total assets Increase US$ 43.9 million (2014)
Total equity Increase US$ 35.2 million (2014)
Number of employees
20 as of March 20, 2015
Website www.catalystpharma.com
Footnotes / references

Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida. The company is developing therapeutics for rare neurological diseases, including Firdapse (3,4-diaminopyridine phosphate, a potassium channel blocker) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and CPP-115 (a GABA transaminase) for the treatment of infantile spasms.

Founded in 2002, Catalyst Pharmaceuticals competed an IPO in 2006. Catalyst focused primarily on developing therapies to prevent addiction until 2012.

In 2009, Catalyst Pharmaceuticals in-licensed worldwide rights to a family of GABA inhibitors including CPP-115 from Northwestern University. Catalyst Pharmaceuticals in-licensed the right to develop Firdapse for the North American market from BioMarin in 2012.

Catalyst Pharmaceuticals obtained a breakthrough therapy designation for Firdapse from the FDA for the development of a treatment of patients suffering from LEMS in 2013. Catalyst Pharmaceuticals has evaluated Firdapse for safety and efficacy in clinical trials. Although not approved by the FDA as of 2015, Firdapse is available to eligible LEMS patients through an Expanded Access Program. Firdapse is also being evaluated as a potential therapy for patients with congenital myasthenic syndromes, for which it has obtained an orphan drug designation from the FDA.

Catalyst Pharmaceuticals is also developing CPP-115 as a treatment for infantile spasms.

The development of Firdapse by Catalyst Pharmaceuticals has brought attention to orphan drug policies that grant market exclusivity as an incentive for companies to develop therapies for small numbers of patients.

News

Catalyst Pharmaceuticals, Inc. (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-03-17 Future report Set alerts
Q3 2020 2020-11-10 Future report Set alerts
Q2 2020 2020-08-10 0.09 0.09
Q1 2020 2020-05-11 0.10 0.10
Q4 2019 2020-03-16 0.08 0.07
Q3 2019 2019-11-12 0.13 0.13
Q2 2019 2019-08-07 0.10 0.10
Q1 2019 2019-05-10 -0.01 -0.01
Q4 2018 2019-03-18 -0.14 -0.14
Q3 2018 2018-11-07 -0.08 -0.08

Ratings

2016-06-14 Reiterated Rating HC Wainwright Buy
2016-04-26 Downgrade Piper Jaffray Overweight to Neutral $6.00 to $1.00
2016-04-26 Downgrade Piper Jaffray Cos. Overweight to Neutral $6.00 to $1.00
2016-03-22 Reiterated Rating Roth Capital Buy
2016-02-23 Reiterated Rating Roth Capital Buy $7.00 to $3.25
2016-02-20 Reiterated Rating SunTrust Buy $7.00 to $6.00
2016-02-20 Reiterated Rating SunTrust Banks Inc. Buy $7.00 to $6.00
2016-02-17 Reiterated Rating Piper Jaffray Buy $10.00 to $6.00
2015-12-25 Reiterated Rating Roth Capital Buy $7.00
2015-09-22 Reiterated Rating Piper Jaffray Overweight $7.00
2015-09-10 Reiterated Rating Roth Capital Buy
2015-08-12 Initiated Coverage Roth Capital Buy
2015-08-11 Reiterated Rating Piper Jaffray Buy $7.00
2015-07-22 Reiterated Rating Roth Capital Buy $7.00
2015-06-24 Initiated Coverage MLV & Co. Buy $14.00
2015-06-18 Reiterated Rating SunTrust Buy $7.00
2015-02-25 Initiated Coverage SunTrust Buy $7.00
2015-02-17 Set Price Target Piper Jaffray Buy $7.00
2014-10-01 Boost Price Target Aegis Positive $7.00
2014-09-30 Reiterated ROTH Capital Buy $5 to $6
2014-09-30 Reiterated Rating Piper Jaffray Positive
2014-09-30 Boost Price Target Roth Capital Buy $5.00 to $6.00
2014-09-16 Reiterated ROTH Capital Buy $3.50 to $5
2014-09-16 Boost Price Target Roth Capital Buy $3.50 to $5.00
2014-09-15 Reiterated H.C. Wainwright Buy $5 to $13
2014-09-15 Boost Price Target HC Wainwright Positive to Buy $5.00 to $13.00
2014-04-14 Reiterated Rating Piper Jaffray Overweight $4.00
2014-03-19 Reiterated Rating Aegis Positive
2014-01-08 Reiterated Rating Aegis Buy
2013-10-21 Reiterated Aegis Capital Buy $4 to $5.50
2013-10-21 Boost Price Target Aegis Buy $4.00 to $5.50
2013-10-16 Boost Price Target Roth Capital $2.75 to $3.75
2013-09-24 Initiated Coverage Maxim Group Buy $4.00
2013-09-06 Reiterated Aegis Capital Buy $3.50 to $4
2013-04-18 Initiated Aegis Capital Buy $2.50
2012-08-27 Upgrade Rodman & Renshaw Mkt Perform to Mkt Outperform $3.70
2009-10-01 Upgrade Merriman Sell to Neutral
2009-05-29 Downgrade Merriman Curhan Ford Buy to Sell
2009-05-29 Downgrade Hapoalim Neutral to Underperform
2008-12-15 Initiated Merriman Curhan Ford Buy
2007-11-28 Initiated Rodman & Renshaw Mkt Outperform $9
2007-01-31 Initiated Stifel Nicolaus Buy $9
2007-01-05 Initiated First Albany Buy $10
2016-06-14 Reiterated Rating HC Wainwright Buy
2016-04-26 Downgrade Piper Jaffray Overweight to Neutral $6.00 to $1.00
2016-04-26 Downgrade Piper Jaffray Cos. Overweight to Neutral $6.00 to $1.00
2016-03-22 Reiterated Rating Roth Capital Buy
2016-02-23 Reiterated Rating Roth Capital Buy $7.00 to $3.25

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
BIOMARIN PHARMACEUTICAL INC 9.93%  (6666667) CPRX / LJPC /
MCENANY PATRICK J President and CEO 7.02%  (4717693) CPRX / KOOL /
HUCKEL HUBERT E MD 1.97%  (1324170) CPRX / KOOL /
Miller Steve VP Development & Management 0.98%  (657687) CPRX /
WALLACE MILTON J 0.80%  (539184) CPRX /
O'Keeffe Charles B 0.76%  (513376) CPRX /
GRANDE ALICIA Chief Accounting Officer 0.59%  (396346) CPRX /
Tierney David S 0.47%  (313401) CPRX /
COELHO PHILIP H 0.33%  (223287) AMPE / CPRX / KOOL /
Winship M Douglas V.P. of Regulatory Operations 0.20%  (134131) CPRX /
DENKHAUS DONALD A 0.15%  (100000) CPRX /
MUTH DAVID D Exec. V.P., Corp. Development 0.07%  (44700) CPRX /
Weinstein Jack V.P., Treasurer & CFO 0.02%  (14493) CPRX /

Comments